SHORT REPORT: THE ACTIVITY OF PAMAQUINE, AN 8-AMINOQUINOLINE DRUG, AGAINST SPOROZOITE-INDUCED INFECTIONS OF PLASMODIUM VIVAX (NEW GUINEA STRAINS)

ANTHONY W. SWEENEY Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Gore Hill, New South Wales, Australia; Darling Point New South Wales, Australia; Army Malaria Institute, Enoggera, Queensland, Australia

Search for other papers by ANTHONY W. SWEENEY in
Current site
Google Scholar
PubMed
Close
,
CHARLES R. B. BLACKBURN Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Gore Hill, New South Wales, Australia; Darling Point New South Wales, Australia; Army Malaria Institute, Enoggera, Queensland, Australia

Search for other papers by CHARLES R. B. BLACKBURN in
Current site
Google Scholar
PubMed
Close
, and
KARL H. RIECKMANN Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Gore Hill, New South Wales, Australia; Darling Point New South Wales, Australia; Army Malaria Institute, Enoggera, Queensland, Australia

Search for other papers by KARL H. RIECKMANN in
Current site
Google Scholar
PubMed
Close
Restricted access

It was reported in 1946 that the administration of pamaquine during the incubation period delayed but did not prevent primary attacks of a New Guinea strain of Plasmodium vivax malaria. The observation that none of the four test subjects in this study had relapses has not previously been published and may have important implications for the evaluation of other 8-aminoquinoline compounds against relapsing vivax malaria.

Author Notes

Reprint requests: Anthony W. Sweeney, Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, West-bourne Street, Gore Hill, New South Wales 2065, Australia.
  • 1

    Muehlens P, 1926. Die Behandlung der natuerlichen menschli\chen Malaria-infektionen mit Plasmochin. Arch Schiffs-u Tropenhyg 30 :25–32.

  • 2

    Sinton JA, Smith S, Pottinger S, 1930. Studies in malaria, with special reference to treatment. Part XII. Further research into the treatment of chronic benign tertian malaria with plasmoquine and quinine. Indian J Med Research 17 :793–814.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    James SP, Nicol MB, Shute PG, 1931. On the prevention of malaria with plasmoquine. Lancet ii :341–342.

  • 4

    Malaria Commission, 1933. Third General Report, Therapeutics of Malaria. Bull Health Org League of Nations 2 :185–285.

  • 5

    Shannon JA, 1946. Rationale underlying the clinical evaluation of antimalarial drugs. Wiselogle, FY ed. A Survey of Antimalarial Drugs, 1941–1945. Washington, DC: Board for the Co-ordination of Malarial Studies, 177–220.

    • PubMed
    • Export Citation
  • 6

    Sweeney T, 2003. Malaria Frontline. Melbourne: Melbourne University Press, 152–155.

    • PubMed
    • Export Citation
  • 7

    Fairley NH, 1946. The chemotherapeutic control of malaria. Schweiz Med Wochenschr 76 :925–932.

  • 8

    LHQ Medical Research Unit, 1946. The Antimalarial Activity of Plasmoquine in Volunteers Exposed to Experimental Mosquito-Transmitted Malaria (New Guinea strains). Fairley Papers 65/9/35. Canberra: Basser Library, Australian Academy of Science.

    • PubMed
    • Export Citation
  • 9

    Sweeney T, 2003. Malaria Frontline. Melbourne: Melbourne University Press, 306.

    • PubMed
    • Export Citation
  • 10

    Fairley NH, Blackburn CR, Andrew RR, Mackerras MJ, Roberts FHS, Allmann SLW, Gregory TS, Backhouse TC, Tonge JI, Black RH, Pope KG, Dunn SR, Swan MSA, Akhurst TAF, Roberts EM, 1947. Sidelights on malaria in man obtained by subinoculation experiments. Trans R Soc Trop Med Hyg 40 :621–676.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Feldman HR, Packer H, Murphy FD, Watson RB, 1946. Pamaquine naphthoate as a prophylactic for malarial infections. Fed Proc 5: 224.

  • 12

    Jones R, Craige B, Alving AS, Whorton M, Pullman TN, Eichelberger L, 1948. A study of the prophylactic effectiveness of several 8-aminoquinolines in sporozoite-induced vivax malaria (Chesson strain). J Clin Invest 27 (Suppl):6–11.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Fairley NH, 1945. Chemotherapeutic suppression and prophylaxis in malaria: an experimental investigation undertaken by medical research teams in Australia. Trans R Soc Trop Med Hyg 38 :311–365.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Anonymous, 1947. Cairns Experimental Group – Relapse Experience. Notes dated February 28, 1947. Fairley Papers 65/32/13. Canberra: Basser Library, Australian Academy of Science.

    • PubMed
    • Export Citation
  • 15

    Krotoski WA, Collins WE, Bray RS, Garnham PCC, Cogswell FB, Gwadz RW, Killick-Kendrick R, Wolf R, Sinden R, Koontz LC, Stanfill PS, 1982. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 31 :1291–1293.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Baird JK, Rieckmann KH, 2003. Vivax series: can primaquine therapy for vivax malaria be improved? Trends Parasitol 19 :115–120.

Past two years Past Year Past 30 Days
Abstract Views 98 77 9
Full Text Views 285 5 1
PDF Downloads 109 6 1
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save